Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder – MarketWatch

by

  1. Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder MarketWatch
  2. Sage Therapeutics stock plunges more than 50% after FDA decision on postpartum depression drug CNBC
  3. Sage Stock: Why The Biotech Lost Half Its Value After The FDA Approved Its Depression Drug Investor’s Business Daily
  4. Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Yahoo Finance
  5. Why Sage Therapeutics Shares Are Sinking Monday – Sage Therapeutics (NASDAQ:SAGE) Benzinga
  6. View Full Coverage on Google News

Read original article here

Leave a Comment